Vascular Anomaly
10
4
6
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.0%
1 terminated out of 10 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (10)
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs
24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs
Pregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 Study
Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible Lesions
Identification of Biomarkers for Patients with Vascular Anomalies
A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease
Vascular Anomaly Pathology and Genomics Biopsy Study
Efficacy and Safety of Sirolimus to Vascular Anomalies